Parkinson’s Disease | Access and Reimbursement | US | 2016
Fewer than ten new brands have launched in the highly generic and crowded Parkinson’s disease (PD) therapy market during the past two decades, but PD’s large and growing elderly population and high polypharmacy rates already impose a moderate burden on U.S. MCOs’ Medicare Advantage Plans, according to DRG research. A wave of new premium-priced brands entering the U.S. market is poised to alter the PD treatment paradigm and impose an even heavier burden on Medicare plans, and with an aging population and surging U.S. healthcare costs, payers have become particularly sensitive to the cost of drugs and medical care. Understanding the impact this payer pressure has on the prescribing of current PD therapies and the market access outlook for emerging therapies is crucial for developers of new and current PD therapeutics facing an increasingly complex market.
